News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Cheryle Barnett, VP, Group Account Director, Fingerpaint Multicultural

Advertisement

Articles by Cheryle Barnett, VP, Group Account Director, Fingerpaint Multicultural

Elevating Multicultural Perspectives in Global Medical Engagement

ByCheryle Barnett, VP, Group Account Director, Fingerpaint Multicultural,Todd Parker, SVP, Managing Director, MedThink SciCom, a Fingerpaint Group Company
July 22nd 2024
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    Brent Saunders: Eyeing New Horizons

    2

    TrumpRX Has a Blind Spot and It Can Redefine Patient Access

    3

    Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial

    4

    The Cost of Fixing Pharma

    5

    FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us